Role of steroid hormone coregulators in health and disease

Hormone Research

Volumn 71, Issue 4, 2009, Pages 194-200

  Thakur, M K ^a   Paramanik, V ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Coactivators; Corepressors; Diseases; Gene regulation; Steroid hormone

Indexed keywords

ACTIVATOR OF THE THYROID AND RETINOIC ACID RECEPTOR; ALTERATION DEFICIENCY IN ACTIVATION 3; ANDROGEN RECEPTOR ACTIVATOR 70; ARI4 PROTEIN; CIZ PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN RECEPTOR ASSOCIATED PROTEIN 140; ESTROGEN RECEPTOR ASSOCIATED PROTEIN 160; HISTONE ACETYLTRANSFERASE PCAF; NSD PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN UBC9; RAP46 PROTEIN; RECEPTOR INTERACTING PROTEIN 140; RECEPTOR INTERACTING PROTEIN 160; REGULATOR PROTEIN; RSP5 PROTEIN; SNURF PROTEIN; SPT6 PROTEIN; STEROID HORMONE; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; SW12 PROTEIN; TRAP100 PROTEIN; TRAP220 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR INTERACTING PROTEIN;

ACETYLATION; BONE; BRAIN FUNCTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE COURSE; GENE ACTIVATION; GENE MUTATION; GENE REPRESSION; HEART FUNCTION; HORMONE ACTION; HUMAN; KIDNEY FUNCTION; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PANCREAS FUNCTION; PATHOGENESIS; PHYSICAL DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTION; SEX DIFFERENTIATION; SEXUAL BEHAVIOR; SHORT SURVEY;

ANIMALS; CHROMATIN; DISEASE; DNA-BINDING PROTEINS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HORMONES; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, NEUROPEPTIDE; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 61349180173     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201107     Document Type: Short Survey

References (59)

1. Evans RM, et al: The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
2. Kumar R, et al: The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res 2005;8:2822-2830.
3. Helmut D, et al: Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 2003;213:79-85.
4. McKenna NJ, Malley BWO: Combinatorial control of gene expression by nuclear receptor and coregulators. Cell 2002;108:465-474.
5. Hong H, et al: GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone-binding domains of the steroid receptors. Proc Natl Acad Sci USA 1996;93:4948-4952.
6. Breeden L, Nasmyth K: Similarity between cell cycle genes of budding yeast and fission yeast and the notch gene of Drosophila. Nature 1987;329:651-654.
7. Yoshinaga SK, et al: Roles of SWI1 SWI2, and SWI3 proteins for translational enhancement by steroid receptors. Science 1992;258:1598-1604.
8. Kwon H, et al: Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 1994;370:477-481.
9. Chiba H, et al: Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila Brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucl Acid Res 1994;10:1815-1820.
10. Peterson CL, et al: Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proc Natl Acad Sci USA 1994;8:2905-2908.
11. Candau R, et al: Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. EMBO J 1997;16:555-565.
12. 300 and CBP are histone acetyltransferase. Cell 1996;87:953-959.
13. Onate SA, et al: Sequence and characterization of a coactivator for the steroid receptor superfamily. Science 1995;270:1354-1357.
14. Kalkhoven E, et al: Isoforms of steroid receptor coactivator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J 1998;17:232-243.
15. McInerney EM, et al: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor. Proc Natl Acad Sci USA 1996;93:10069-10073.
16. 3 receptor: a network of coactivator interactions. Gene 2000;246:9-21.
17. Hirochika K, et al: The chromatin remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003;113:905-917.
18. Janknecht R: The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 2002;17:657-668.
19. Yeung PL, et al: Nuclear localization of coactivator RAC3 is mediated by a bipartite NLS and importin α3. Biochem Biophys Res Commun 2006;1:13-24.
20. Balmer NN, et al: Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol 2006;12:1593-1605.
21. Leader JE, et al: Epigenetics and the estrogen receptor. Ann NY Acad Sci 2006;1089:73-87.
22. Bertolotti A, et al: hTAF(II)68, a novel RNA/ ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996;18:5022-5031.
23. Domanskyi A, et al: Biochemical characterization of androgen receptor-interacting protein 4. Biochem J 2006;3:789-795.
24. Saether T, et al: The chromatin remodeling factor Mi-2α acts as a novel co-activator for human c-Myb. J Biol Chem 2007;282:13994-14005.
25. Horwitz KB, et al: Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996;10:1167-1177.
26. Baniahmad A, et al: A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor. EMBO J 1992;11:1015-1023.
27. Takahiro I, Lazar MA: The NCoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol Cell Biol 2003;23:5122-5131.
28. Lopez-Garcia J, et al: ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acid Res 2006;21:6126-6136.
29. Wolffe AP, Pruss D: Targeting chromatin disruption: transcription regulators thatacetylate histones. Cell 1996;84:817-819.
30. Li J, et al: Both corepressor proteins SMRT and NCoR exist in large protein complexes containing HDAC3. EMBO J 2000;19:4342-4350.
31. Wang LH, et al: Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006;6:4874-4899.
32. Fred P, et al: Rubinstein-Taybi syndrome caused by mutations in the transcriptional coactivator CBP. Nature 2002;376:348-351.
33. Yao TP, et al: Gene dosage-dependent embryronic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998;93:361-372.
34. Kung AL, et al: Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Gen Dev 2000;14:272-277.
35. Neri C: New light on polyglutamine neurodegenerative disorders: inference with transcription. Trend Mol Med 2001;7:283-284.
36. Kobayashi S, et al: FHL2, UBC9 and PIAS1 are novel estrogen receptor α-interacting proteins. Endocr Res 2004;4:617-621.
37. Den Hollander P, et al: Ciz1, a novel DNAbinding coactivator of the estrogen receptor α confers hypersensitivity to estrogen action. Cancer Res 2006;22:11021-11029.
38. Glass CK: Going nuclear in metabolic and cardiovascular disease. J Clin Invest 2006;3:556-560.
39. Frederic P, et al: SRC-1 and TIF2 control energy balance white and brown adipose tissues. Cell 2002;111:931-941.
40. Ito M, et al: Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol Cell 2000;5:683-693.
41. Imasaki K, et al: Androgen insensitivity syndrome due to new mutations in the DNAbinding domain of the androgen receptor. Mol Cell Endocrinol 1996;120:15-24.
42. Eli YA, Jon DH: Single-gene mutations resulting in reproductive dysfunction in women. N Engl J Med 1999;340:709-718.
43. Zoppi S, et al: Complete testicular feminization caused by amino-terminal truncation of the androgen receptor with downstream initiation. J Clin Invest 1993;91:1105-1112.
44. Li W, et al: Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 2005;9:2273-2282.
45. Nan X, et al: Transcriptional repressions by methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
46. Batsche E, et al: Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. J Biol Chem 2005;280:19746-19756.
47. Kouzarides T: Histone acetylases and deacetylases in cell proliferation. Curr Opin Gen Dev 1999;9:140-148.
48. Wong CW, Privalsky ML: Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol 1998;18:5500-5510.
49. Cui Y, et al: Metastasis-associated protein 2 is a repressor of estrogen receptor α whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol 2006;9:2020-2035.
50. Rayner K, et al: NM23-H2, an estrogen receptor β-associated protein, shows diminished expression with progression of atherosclerosis. Am J Physiol 2007;292:R743-R750.
51. Fenrick R, et al: Both TEL and AML-1 contribute repression domains to the t(12; 21) fusion protein. Mol Cell Biol 1999;10:6566-6574.
52. Lutterbach B, et al: A target of t(8; 21) in acute leukemia interacts with the NCoR and mSin3 corepressors. Mol Cell Biol 1988;18:7176-7184.
53. Adcock IM, et al: Histone deacetylation: an important mechanism in inflammatory lung diseases. J Chron Obstruct Pulmon Dis 2005;4:445-455.
54. Secrist JP, et al: HDAC inhibitors for the treatment of cancer. Curr Opin Invest Drugs 2003;4:1422-1427.
55. Bicaku E, et al: Selective inhibition of histone deacetylase 2 silences progesterone receptormediated signaling. Cancer Res 2008;68:1513-1519.
56. Wang J, et al: Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999;12:2766-2769.
57. Michael LF, et al: The pharmacology of LXR. Med Chem 2005;8:729-740.
58. De Nigris F, et al: Coregulators new insights in the transcriptional activity and coregulator molecules in the arterial wall. Int J Cardiol 2002;2-3:153-168.
59. Tanaka T, et al: Ligands for peroxisome proliferator-activated receptors and inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61:2424-2428.